Trial
NCT00550342
Rituximab Treatment of Focal Segmental Glomerulosclerosis
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators
Genentech, Inc.; Indiana University
Condition
Focal Segmental Glomerulosclerosis (FSGS)
Intervention
rituximab
Why stopped
Problems with drug supply
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-06